Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...

trametinib monotherapy expected in 2025 SAN ... and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., chairman, CEO, and ...

The therapy is the fourth clinical-stage programme derived from the company’s chemoproteomics discovery platform.

We have assembled one of the deepest RAS/MAPK pathway-focused pipeline in the ... the analysis of pooled Phase 1 and Phase 2 naporafenib plus trametinib data covers two clinical trials with ...

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...

San Diego, California Friday, April 4, 2025, 16:00 Hrs [IST] ...

and may deliver increased efficacy in combination with other RAS/MAPK pathway inhibitors Approximately 20 percent of all cancers are driven by mutations of the RAS family of genes 1 Vividion ...

We have assembled one of the deepest RAS/MAPK pathway-focused pipeline in the industry ... the analysis of pooled Phase 1 and Phase 2 naporafenib plus trametinib data covers two clinical trials with ...

We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was ...